{"id":2098,"date":"2026-10-05T19:16:57","date_gmt":"2026-10-05T10:16:57","guid":{"rendered":"https:\/\/globalregulatorypartners.co.jp\/?post_type=news&p=2098"},"modified":"2026-10-06T11:12:38","modified_gmt":"2026-10-06T02:12:38","slug":"baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di","status":"publish","type":"news","link":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/","title":{"rendered":"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI"},"content":{"rendered":"\n

Special feature:<\/em> \u300c\u70b9\u9f3b\u30ec\u30b9\u30ad\u30e5\u30fc\u85ac\u3001\u96c6\u7d50\u3002\u300d<\/em><\/p>\n\n\n\n

Link to Document HERE<\/a><\/strong><\/p>\n\n\n\n

Global Regulatory Partners GK (GRP Japan)<\/strong> is pleased to share that Baqsimi\u00ae Nasal Powder<\/strong>, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI)<\/em>.<\/strong><\/p>\n\n\n\n

Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

The September issue includes a special feature titled \u300c\u70b9\u9f3b\u30ec\u30b9\u30ad\u30e5\u30fc\u85ac\u3001\u96c6\u7d50\u3002\u300d, focusing on nasal rescue medicines used in situations where rapid and practical administration is important.<\/p>\n\n\n\n

The feature covers several therapeutic areas, including severe hypoglycemia, epileptic seizures and anaphylaxis, reflecting growing attention to intranasal drug delivery in emergency care.<\/p>\n\n\n\n

BAQSIMI\u00ae AND SEVERE HYPOGLYCEMIA<\/strong><\/p>\n\n\n\n

Within the section on severe hypoglycemia, Nikkei DI introduces Baqsimi\u00ae Nasal Powder (glucagon) as a nasal glucagon treatment and presents practical information on its administration in an emergency.<\/p>\n\n\n\n

The article includes photographs illustrating the single-use nasal device and the administration procedure, helping provide healthcare professionals with a practical overview of how the product is used.<\/p>\n\n\n\n

For GRP Japan, the inclusion of Baqsimi\u00ae in this professional feature provides an opportunity for healthcare professionals to learn more about severe hypoglycemia and its management.<\/p>\n\n\n\n

Publication<\/strong><\/td>Nikkei Drug Information (Nikkei DI)<\/td><\/tr>
Issue<\/strong><\/td>September 2026<\/td><\/tr>
Special Feature<\/strong><\/td>\u300c\u70b9\u9f3b\u30ec\u30b9\u30ad\u30e5\u30fc\u85ac\u3001\u96c6\u7d50\u3002\u300d<\/td><\/tr>
Featured GRP Product<\/strong><\/td>Baqsimi\u00ae Nasal Powder<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Marketing Authorization Holder in Japan: Global Regulatory Partners GK<\/strong><\/p>\n\n\n\n

Source: Source: Nikkei Drug Information, September 2026 issue.
Cover image reproduced with permission of the publisher.
Baqsimi\u00ae is a registered trademark of its respective owner.<\/p>\n","protected":false},"featured_media":0,"template":"","categories":[18],"class_list":["post-2098","news","type-news","status-publish","hentry","category-announcement"],"acf":[],"yoast_head":"\nBaqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners<\/title>\n<meta name=\"description\" content=\"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners\" \/>\n<meta property=\"og:description\" content=\"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/\" \/>\n<meta property=\"og:site_name\" content=\"Global Regulatory Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-06T02:12:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2026\/10\/Nikkei-DI-cover-2026-09.png\" \/>\n\t<meta property=\"og:image:width\" content=\"241\" \/>\n\t<meta property=\"og:image:height\" content=\"320\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/\",\"url\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/\",\"name\":\"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Nikkei-DI-cover-2026-09.png\",\"datePublished\":\"2026-10-05T10:16:57+00:00\",\"dateModified\":\"2026-10-06T02:12:38+00:00\",\"description\":\"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/#primaryimage\",\"url\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Nikkei-DI-cover-2026-09.png\",\"contentUrl\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Nikkei-DI-cover-2026-09.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/\",\"name\":\"Global Regulatory Partners\",\"description\":\"Patients first, Faster access, Healthier lives\",\"publisher\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#organization\",\"name\":\"Global Regulatory Partners\",\"url\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/logo-main-color.svg\",\"contentUrl\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/logo-main-color.svg\",\"caption\":\"Global Regulatory Partners\"},\"image\":{\"@id\":\"https:\\\/\\\/globalregulatorypartners.co.jp\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners","description":"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/","og_locale":"en_US","og_type":"article","og_title":"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners","og_description":"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.","og_url":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/","og_site_name":"Global Regulatory Partners","article_modified_time":"2026-10-06T02:12:38+00:00","og_image":[{"width":241,"height":320,"url":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2026\/10\/Nikkei-DI-cover-2026-09.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/","url":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/","name":"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI | Announcement | Global Regulatory Partners","isPartOf":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/#primaryimage"},"image":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/#primaryimage"},"thumbnailUrl":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2026\/10\/Nikkei-DI-cover-2026-09.png","datePublished":"2026-10-05T10:16:57+00:00","dateModified":"2026-10-06T02:12:38+00:00","description":"Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi\u00ae Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.","breadcrumb":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/#primaryimage","url":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2026\/10\/Nikkei-DI-cover-2026-09.png","contentUrl":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2026\/10\/Nikkei-DI-cover-2026-09.png"},{"@type":"BreadcrumbList","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/baqsimi-nasal-powder-featured-in-the-september-2026-issue-of-nikkei-di\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/globalregulatorypartners.co.jp\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/"},{"@type":"ListItem","position":3,"name":"Baqsimi\u00ae Nasal Powder Featured in the September 2026 Issue of Nikkei DI"}]},{"@type":"WebSite","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#website","url":"https:\/\/globalregulatorypartners.co.jp\/en\/","name":"Global Regulatory Partners","description":"Patients first, Faster access, Healthier lives","publisher":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/globalregulatorypartners.co.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#organization","name":"Global Regulatory Partners","url":"https:\/\/globalregulatorypartners.co.jp\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#\/schema\/logo\/image\/","url":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2025\/09\/logo-main-color.svg","contentUrl":"https:\/\/globalregulatorypartners.co.jp\/wp-content\/uploads\/2025\/09\/logo-main-color.svg","caption":"Global Regulatory Partners"},"image":{"@id":"https:\/\/globalregulatorypartners.co.jp\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/globalregulatorypartners.co.jp\/en\/wp-json\/wp\/v2\/news\/2098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalregulatorypartners.co.jp\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/globalregulatorypartners.co.jp\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/globalregulatorypartners.co.jp\/en\/wp-json\/wp\/v2\/media?parent=2098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalregulatorypartners.co.jp\/en\/wp-json\/wp\/v2\/categories?post=2098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}